

Acute Respiratory Distress Syndrome - Pipeline Review, H1 2020

<https://marketpublishers.com/r/A1B15739EF8EN.html>

Date: January 2020

Pages: 129

Price: US\$ 2,000.00 (Single User License)

ID: A1B15739EF8EN

Abstracts

Acute Respiratory Distress Syndrome - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H1 2020, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.

Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress

Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 6, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).

The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

Contents

Introduction

Acute Respiratory Distress Syndrome - Overview

Acute Respiratory Distress Syndrome - Therapeutics Development

Acute Respiratory Distress Syndrome - Therapeutics Assessment

Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics
Development

Acute Respiratory Distress Syndrome - Drug Profiles

Acute Respiratory Distress Syndrome - Dormant Projects

Acute Respiratory Distress Syndrome - Discontinued Products

Acute Respiratory Distress Syndrome - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by A6 Pharmaceuticals LLC, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Aqualung Therapeutics Corp, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Athersys Inc, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Bayer AG, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Cells for Cells SA, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Commence Bio Inc, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Cynata Therapeutics Ltd, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Emergent BioSolutions Inc, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Eunoia Biotech LLC, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Exvastat Ltd, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by HistoCell SL, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Hydra Biosciences Inc, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Implicit Bioscience Ltd, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by In2cure AB, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by IsletOne AB, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Liminal BioSciences Inc, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by LTT Bio-Pharma Co Ltd, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Meridigen Biotech Co Ltd, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Nano Biotherapeutics Inc, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Northern Therapeutics Inc, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Orbsen Therapeutics Ltd, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Restore Therapeutics LLC, H1 2020

Acute Respiratory Distress Syndrome - Pipeline by Savara Inc, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by SolAeroMed Inc, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Vasomune Inc, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Windtree Therapeutics Inc, H1 2020
Acute Respiratory Distress Syndrome - Dormant Projects, H1 2020
Acute Respiratory Distress Syndrome - Dormant Projects, H1 2020 (Contd..1), H1 2020
Acute Respiratory Distress Syndrome - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

A6 Pharmaceuticals LLC

Aqualung Therapeutics Corp

Athersys Inc

Bayer AG

Cells for Cells SA

Commence Bio Inc

Cynata Therapeutics Ltd

Emergent BioSolutions Inc

Eunoia Biotech LLC

Exvastat Ltd

Faron Pharmaceuticals Oy

Histocell SL

Hydra Biosciences Inc

Implicit Bioscience Ltd

In2cure AB

IsletOne AB

Liminal BioSciences Inc

LTT Bio-Pharma Co Ltd

Meridigen Biotech Co Ltd

Nano Biotherapeutics Inc

Northern Therapeutics Inc

Orbsen Therapeutics Ltd
Restore Therapeutics LLC
Savara Inc
SolAeroMed Inc
Vasomune Inc
Windtree Therapeutics Inc

I would like to order

Product name: Acute Respiratory Distress Syndrome - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/A1B15739EF8EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A1B15739EF8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970